-

Award: Boehringer Ingelheim is Global Top Employer 2022

• Boehringer Ingelheim advances to one of eleven global top employers worldwide

• Awards in 29 countries and in Europe, the Latin America, and Asia-Pacific regions

• High scores in values, ethics and integrity serve as a driver for a strong corporate innovation culture

INGELHEIM, Germany--(BUSINESS WIRE)--The Top Employers Institute awarded Boehringer Ingelheim for the second year in succession a “Global Top Employer”, one of the world’s eleven best employers. The award shows that the research-driven pharmaceutical company is strongly oriented to the needs and well-being of its employees. Boehringer Ingelheim has been listed among the top employers in many countries and regions for the past eight years. This year, Boehringer Ingelheim will receive the award in 29 countries, as well as in Europe and the Latin America, and Asia-Pacific regions. The independent Top Employers Institute certifies employers worldwide who wish to offer their employees excellent working conditions and support their development. Certification is based on a multi-level program to examine human resources management with detailed final feedback.

Boehringer Ingelheim continued to thrive in the area of employee engagement where it particularly stands out with regards to rewards and recognition, compared to its competitors. The Top Employers Institute also highlighted the agile work environment as well as the company’s values, ethics and integrity that result in the strong, inclusive corporate culture.

“The human dimension is a central part of Boehringer Ingelheim. This includes the feeling of belonging and an ongoing attention on everyone’s wellbeing at work. The certification as Global Top Employer recognizes once again that our work environment makes the company stand out as an employer”, says Dr Sven Sommerlatte, Global Head of Human Resources at Boehringer Ingelheim. “We are committed to empowering all people and foster diverse teams that deliver inclusive solutions. This forms the basis for our corporate innovation culture.”

An example of employee orientation is the well-established mobile working. It helps, among other, to ensure that during the COVID pandemic, employees are empowered to actively adapt their work to health protection requirements and to ensure business continuity. This also applies for virtual onboarding processes for which the company established concepts for new employees working from home. Another point highlighted by the jury refers to the ethical, inclusive approach to corporate decisions and a clear focus on the transfer and application of company values. The family business also takes care of individual development opportunities through tailor-made education and training programs throughout the employee’s working life.

As a research-driven pharmaceutical company, Boehringer Ingelheim is committed to create value in areas of unmet medical need and engage with communities and society to change lives for the better. This has recently been exemplified through the extension of Boehringer Ingelheim’s initiative Making More Health (MMH) called “Boehringer Ingelheim Social Engagements” with a funding of EUR 50 million.

Intended audiences:

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

Please click on the following link for ‘Notes to Editors’:

https://www.boehringer-ingelheim.com/about-us/corporate-profile/award-boehringer-ingelheim-global-top-employer-2022

Contacts

Boehringer Ingelheim
Corporate Communications
Sarah Soetbeer
Telefon: 06132 – 77 183874
Email: press@boehringer-ingelheim.com

Boehringer Ingelheim


Release Versions

Contacts

Boehringer Ingelheim
Corporate Communications
Sarah Soetbeer
Telefon: 06132 – 77 183874
Email: press@boehringer-ingelheim.com

More News From Boehringer Ingelheim

Boehringer Ingelheim receives approval for SENVELGO® in Europe: the first oral liquid medication for diabetic cats

INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim, a global leader in animal health, has received marketing authorization from the European Commission for SENVELGO® (active ingredient: velagliflozin), marking a significant step for the treatment of feline diabetes in Europe. Globally, SENVELGO® is the first once-daily liquid oral solution for the reduction of hyperglycemia in cats with non-insulin-dependent diabetes mellitus. This breakthrough innovation will make it easier for cat owne...

Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma

INGELHEIM, Germany & BASEL, Switzerland--(BUSINESS WIRE)--Boehringer Ingelheim today announced the acquisition of privately-held T3 Pharmaceuticals AG (“T3 Pharma”), a clinical stage Swiss biotech company, for an amount of up to 450 million CHF. T3 Pharma has developed a proprietary therapy platform that uses live bacteria to deliver immune-modulating proteins to cancer cells and tumor micro-environments. Despite the significant transformation of the cancer treatment landscape by immunotherapie...

Boehringer Ingelheim’s SPEVIGO® (spesolimab) wins 2023 Prix Galien USA Best Orphan/Rare Diseases Solution Award

INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today announced that SPEVIGO® (spesolimab) has been recognized as Best Orphan/Rare Diseases Solution of 2023 by the Galien Foundation. The Prix Galien USA Award was presented last night in New York. Prix Galien Foundation fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health. In 2022 the U.S. Food and Drug Administration approved spesolimab as a treatment option for GPP flares in adults...
Back to Newsroom